Bayer Bolsters Ophthalmology Portfolio with $2.45 Billion Acquisition of Perfuse Therapeutics

Leveraging a strategic pivot to counteract looming patent cliffs for its blockbuster assets, Bayer AG announced on May 6, 2026, a definitive agreement to acquire San Francisco-based Perfuse Therapeutics. The deal, valued at up to $2.45 billion, positions the German life sciences giant to dominate the next generation of therapies for ischemia-induced ocular diseases, specifically targeting glaucoma and diabetic retinopathy (DR).

Most “AI for Diligence” tools are lying to you. The truth is, they are just ChatGPT wrappers. Experience what real AI for Diligence looks like, built like Claude Code, but for M&A/ PE Diligence:

💼 When Claude Code Marries Due Diligence!

The transaction includes an upfront payment of $300 million, with the remaining $2.15 billion tied to development, regulatory, and commercial milestones. This structure reflects a broader trend in biopharmaceutical M&A valuations 2026, where acquirers increasingly utilize contingent value rights (CVRs) to mitigate clinical-stage risks while securing high-potential innovation.

Strategic Rationale: Filling the Post-Eylea Revenue Gap

For Bayer, the acquisition is a calculated defensive and offensive move. Its flagship ophthalmology drug, Eylea, is facing intensified biosimilar competition and price erosion in key markets including the U.K., Canada, and Japan. With the U.S. patent on Eylea set to expire in 2027, Bayer management has identified a “dent” in revenue that must be filled by novel, disease-modifying assets rather than mere incremental improvements.

Perfuse’s lead asset, PER-001, is a first-in-class small molecule endothelin receptor antagonist delivered via a sustained-release intravitreal implant. Unlike current standards of care that focus primarily on lowering intraocular pressure, PER-001 targets retinal non-perfusion—the underlying ischemia that leads to cell death and blindness. This ophthalmology pipeline acquisition strategy allows Bayer to address a combined global patient population of over 220 million people suffering from glaucoma and DR.

Table 1: Key Deal Terms and Financial Framework

Sector Dynamics: The Race for Disease Modification

The ophthalmology sector has seen a resurgence in 2025 and early 2026, driven by an aging global population and a shift toward long-acting delivery systems. Industry leaders such as Roche and Merck have also made significant bets, with Merck’s $1.3 billion purchase of EyeBio in 2025 signaling a high premium for assets that reduce the frequency of patient injections.

Bayer’s integration of PER-001 fits its “impact-by-innovation” strategy. The drug’s six-month dosing interval addresses the significant “treatment burden” associated with monthly or bimonthly injections, a key metric for post-patent cliff revenue diversification. Institutional investors have reacted cautiously but positively; Bayer’s stock has shown resilience as the market anticipates a return to mid-single-digit growth by 2027.

Table 2: Comparative Pipeline Outlook – Retinal Vascular Disease

Operational Implications and Leadership

Under the leadership of Bill Anderson, Bayer has moved toward a more decentralized, AI-enabled operating model. This “Dynamic Shared Ownership” approach is intended to accelerate the development of PER-001 by integrating Perfuse’s specialized R&D expertise in South San Francisco with Bayer’s global commercial infrastructure.

While the deal is expected to result in some consolidation of back-office functions, Bayer has emphasized the retention of Perfuse’s scientific leadership, including founder Sevgi Gurkan, MD. This focus on “scientific selectivity” is a hallmark of cross-border M&A trends 2026, where the value lies in the intellectual property and clinical trajectory rather than physical assets.

Market Outlook

The deal is subject to customary antitrust clearances. Analysts at Goldman Sachs and J.P. Morgan note that while $2.45 billion is a significant commitment for a Phase II asset, the scarcity of neuroprotective treatments in ophthalmology justifies the premium. Should PER-001 achieve its Phase III endpoints and regulatory approval, it could become a multi-billion dollar “anchor” for Bayer’s pharmaceutical division through the 2030s, effectively transitioning the company from a reliance on Eylea to a more diversified, multimodal portfolio.